 |
|
Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma?
Sang-Gon Park
Korean J Intern Med. 2019;34(4):775-776. Published online 2019 Jul 1 DOI: https://doi.org/10.3904/kjim.2019.182
|
|
Citations to this article as recorded by
 Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma
Shinya Ohata, Kei Takenaka, Daisuke Sugiyama, Takeshi Sugimoto, Estella M. Matutes
Advances in Hematology.2022; 2022: 1. CrossRef Clinical Post-Transplant Lymphoproliferative Disorders
Ziba Aghsaeifard, Reza Alizadeh
Cardiovascular & Hematological Disorders-Drug Targets.2022; 22(2): 96. CrossRef
|